HomeDMN • FRA
add
Diamyd Medical AB
Previous close
€0.76
Day range
€0.79 - €0.79
Year range
€0.54 - €1.74
Market cap
1.13B SEK
Avg Volume
20.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Feb 2024info | Y/Y change |
|---|---|---|
Revenue | 26.00K | -76.99% |
Operating expense | 27.96M | 22.46% |
Net income | -29.25M | -17.14% |
Net profit margin | -112.50K | -409.13% |
Earnings per share | — | — |
EBITDA | -27.37M | -20.54% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Feb 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 137.15M | 34.99% |
Total assets | 226.48M | 28.90% |
Total liabilities | 45.26M | 135.13% |
Total equity | 181.22M | — |
Shares outstanding | 94.95M | — |
Price to book | 0.40 | — |
Return on assets | -29.31% | — |
Return on capital | -36.67% | — |
Cash Flow
Net change in cash
| (SEK) | Feb 2024info | Y/Y change |
|---|---|---|
Net income | -29.25M | -17.14% |
Cash from operations | -35.43M | -39.59% |
Cash from investing | -3.47M | 9.63% |
Cash from financing | -209.00K | — |
Net change in cash | -39.57M | -34.97% |
Free cash flow | -29.83M | -46.28% |
About
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for diabetes. The company is developing two products.
The company is headquartered in Stockholm, and maintains a manufacturing facility in Umeå. Wikipedia
Founded
1984
Website
Employees
26
